One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
OrganiGram Holdings  logo
OrganiGram Holdings OGI
$ 0.94 0.38%
report update icon

Quarterly report 2024-Q4
added 10-15-2026

OrganiGram Holdings Income Statement 2024-2011 | OGI

Brief overview of financial performance at OrganiGram Holdings

The conclusions below are based on five years of reported results. The revenue attributed to OrganiGram Holdings moved from 80.4 million Canadian dollars to 160 million Canadian dollars between the two endpoints. The five-year change reached +98.8%, while CAGR stood at 14.7%. Revenue followed a strong upward trend without signs of stagnation.

Gross profit changed from 48.5 million Canadian dollars to 47.5 million Canadian dollars (−1.9%). Cost of revenue developed less favorably than sales and pressured gross profitability. The gross margin was 60.3% at the start and 29.7% at the end. The business retained less gross profit from each unit of revenue.

The operating result measured by EBITDA moved from 5.5 million Canadian dollars to −35.7 million Canadian dollars, or −750.1%. Operating performance weakened relative to revenue. EBITDA margin moved from 6.8% to −22.3%. The margin contraction indicates weaker operating efficiency.

Across the five years, the net result shifted from −9.5 million Canadian dollars to −45.4 million Canadian dollars. The period ended with a larger loss than it began with.

Market capitalization changed from 365 million Canadian dollars to 151 million Canadian dollars (−58.7%). The market is not yet fully reflecting the fundamental progress.

Summary assessment

The results contain several connected negative signals. The constructive conclusion rests on a larger revenue base. Caution is warranted because of pressure from direct costs, a weaker market valuation and pressure on operating profitability. Further direction will depend on top-line growth, operating profitability, and net income.

Annual Income Statement OrganiGram Holdings

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

151 M 104 M 121 M 382 M 356 M 365 M - - 75.6 M - 3.89 M 41.7 M 176 M 170 M

Shares

95.3 M 81.3 M 77.2 M 256 M 195 M 141 M - - 58.7 M - 8.29 M 8.29 M 6.99 M 7.33 M

Historical Prices

1.58 1.28 1.57 1.49 1.83 2.59 - - - - - - - -

Net Income

-45.4 M -249 M -14.3 M -131 M -136 M -9.54 M 20.5 M -10.9 M 847 K -9.72 M - -375 K -140 K -

Revenue

160 M 162 M 146 M 79.2 M 86.8 M 80.4 M 12.4 M 5.71 M 6.13 M 81.1 K - - - -

Cost of Revenue

111 M 136 M 119 M 104 M 105 M 37.8 M 5.52 M - - - - - - -

Gross Profit

47.5 M 38 M 31.6 M -28.4 M -56.5 M 48.5 M 52.5 M -3.13 M 5.31 M -321 K - - - -

Operating Income

-35.7 M -263 M -43.2 M -91.8 M -146 M 5.49 M 36.4 M - - - - - - -

EBITDA

-35.7 M -263 M -43.2 M -91.8 M -146 M 5.49 M 36.9 M -10.8 M 2.03 M -9.47 M - -375 K -140 K -

Operating Expenses

- - - - 41.4 M 42.4 M 16.1 M 8.04 M 4.07 M 9.35 M - - - -

General and Administrative Expenses

19.1 M 18.4 M 18.3 M 12.8 M 29.9 M 26.7 M 9.27 M 4.78 M 2.31 M 8.87 M - 319 K 140 K -

All numbers in CAD currency

Quarterly Income Statement OrganiGram Holdings

2024-Q4 2024-Q3 2023-Q4 2023-Q3 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

- 95.3 M - 81.3 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

- -45.4 M - -249 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

- 160 M - 162 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

- 111 M - 136 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

- 47.5 M - 38 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

- -35.7 M - -263 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- -35.7 M - -263 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

- 19.1 M - 18.4 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in CAD currency

The income statement is one of the three key financial reports of a company OrganiGram Holdings (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Drug manufacturers industry

Issuer Price % 24h Market Cap Country
HEXO Corp. HEXO Corp.
HEXO
- 2.45 % $ 38.1 M canadaCanada
Calliditas Therapeutics AB (publ) Calliditas Therapeutics AB (publ)
CALT
- -0.1 % $ 2.03 B schwedenSchweden
AcelRx Pharmaceuticals AcelRx Pharmaceuticals
ACRX
- 7.5 % $ 6.35 M usaUSA
Assertio Holdings Assertio Holdings
ASRT
- - $ 150 M usaUSA
Jupiter Wellness Jupiter Wellness
JUPW
- - $ 33.6 M usaUSA
Neoleukin Therapeutics Neoleukin Therapeutics
NLTX
- - $ 193 M canadaCanada
ProPhase Labs ProPhase Labs
PRPH
- - $ 5.07 M usaUSA
Zomedica Corp. Zomedica Corp.
ZOM
- -0.21 % $ 98 M usaUSA
Perrigo Company plc Perrigo Company plc
PRGO
$ 15.91 -1.64 % $ 2.2 B usaUSA
Cumberland Pharmaceuticals Cumberland Pharmaceuticals
CPIX
$ 8.17 2.64 % $ 121 M usaUSA
Evolus Evolus
EOLS
$ 7.4 0.41 % $ 477 M usaUSA
Tricida Tricida
TCDA
- - $ 3.25 M usaUSA
Avadel Pharmaceuticals plc Avadel Pharmaceuticals plc
AVDL
- - $ 2.06 B franceFrance
DURECT Corporation DURECT Corporation
DRRX
- - $ 50.1 M usaUSA
Aerie Pharmaceuticals Aerie Pharmaceuticals
AERI
- - $ 754 M usaUSA
Endo International plc Endo International plc
ENDP
- - $ 28.9 M irlandaIrlanda
Radius Health Radius Health
RDUS
- - $ 1.42 B usaUSA
Recro Pharma Recro Pharma
REPH
- -4.76 % $ 65.3 M usaUSA
Adamis Pharmaceuticals Corporation Adamis Pharmaceuticals Corporation
ADMP
- 0.86 % $ 117 M usaUSA
Agile Therapeutics Agile Therapeutics
AGRX
- 10.11 % $ 58.2 M usaUSA
Evoke Pharma Evoke Pharma
EVOK
- - $ 36.6 M usaUSA
Alimera Sciences Alimera Sciences
ALIM
- - $ 142 M usaUSA
PLx Pharma PLx Pharma
PLXP
- -27.8 % $ 2.56 M usaUSA
Athenex Athenex
ATNX
- -23.39 % $ 1.76 M usaUSA
Lannett Company Lannett Company
LCI
- 1.15 % $ 7.11 M usaUSA
Zynerba Pharmaceuticals Zynerba Pharmaceuticals
ZYNE
- - $ 55.5 M usaUSA
Aurora Cannabis Aurora Cannabis
ACB
$ 3.96 -0.25 % $ 217 M canadaCanada
Catalent Catalent
CTLT
- - $ 11.5 B usaUSA
Eagle Pharmaceuticals Eagle Pharmaceuticals
EGRX
- -39.89 % $ 27.7 M usaUSA
OptiNose OptiNose
OPTN
- - $ 1.08 B usaUSA
Emergent BioSolutions Emergent BioSolutions
EBS
$ 6.2 -1.43 % $ 332 M usaUSA
PetIQ PetIQ
PETQ
- 1.64 % $ 400 M usaUSA
Pacira BioSciences Pacira BioSciences
PCRX
$ 36.33 -0.14 % $ 1.62 B usaUSA
Rockwell Medical Rockwell Medical
RMTI
$ 7.08 -2.07 % $ 255 M usaUSA
Solid Biosciences Solid Biosciences
SLDB
$ 6.41 0.16 % $ 561 M usaUSA
Tilray Tilray
TLRY
$ 2.92 -3.63 % $ 327 M canadaCanada
TherapeuticsMD TherapeuticsMD
TXMD
$ 1.9 1.06 % $ 22 M usaUSA
Veru Veru
VERU
$ 2.3 -3.36 % $ 33.7 M usaUSA
Viatris Viatris
VTRS
$ 18.45 -1.07 % $ 21.2 B usaUSA
Harrow Health Harrow Health
HROW
$ 28.24 0.61 % $ 1.04 B usaUSA
Canopy Growth Corporation Canopy Growth Corporation
CGC
$ 0.67 -6.67 % $ 200 M canadaCanada
Organogenesis Holdings Organogenesis Holdings
ORGO
$ 0.99 -2.81 % $ 125 M usaUSA
SCYNEXIS SCYNEXIS
SCYX
$ 3.79 -0.39 % $ 189 M usaUSA
Sundial Growers Sundial Growers
SNDL
$ 1.28 0.39 % $ 330 M canadaCanada
Sonoma Pharmaceuticals Sonoma Pharmaceuticals
SNOA
$ 1.14 -0.87 % $ 1.92 M usaUSA
cbdMD cbdMD
YCBD
$ 0.38 -2.14 % $ 1.53 M usaUSA
Bausch Health Companies Bausch Health Companies
BHC
$ 6.45 0.55 % $ 2.39 B canadaCanada
Cronos Group Cronos Group
CRON
$ 3.39 3.35 % $ 1.3 B canadaCanada
China Pharma Holdings China Pharma Holdings
CPHI
$ 0.7 -3.78 % $ 3 M chinaChina